Suppr超能文献

肢端肥大症伴初诊口服葡萄糖耐量试验阴性:病例报告。

Acromegaly with initial negative oral glucose tolerance test: a case report.

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan, ROC.

Department of Medicine, MacKay Medical College, New Taipei City, Taiwan, ROC.

出版信息

J Med Case Rep. 2023 Aug 6;17(1):333. doi: 10.1186/s13256-023-04064-z.

Abstract

BACKGROUND

Acromegaly can be diagnosed by a growth hormone value ≥ 1 µg/L following an oral glucose tolerance test. However, normal growth hormone suppression following oral glucose tolerance test may not exclude acromegaly.

CASE PRESENTATION

We present a case of a 55-year-old Chinese man with pituitary macroadenoma incidentally noted after a traffic accident. He reported feet enlargement in the past few years. At the beginning, elevated insulin-like growth factor-1 was noted with growth hormone value < 1 µg/L after oral glucose tolerance test. Fracture-related high insulin-like growth factor-1 was suspected. Insulin-like growth factor-1 decreased gradually but was still above the upper limit of normal . However, he suffered from dizziness 1 year later and insulin-like growth factor-1 increased again. Besides, secondary hypocortisolism developed. The size of the pituitary macroadenoma was stationary. Follow-up oral glucose tolerance test showed a growth hormone value > 1 µg/L. Endoscopic endonasal approach to the remove pituitary macroadenoma was performed subsequently. After the resection of the pituitary macroadenoma, pathology showed positive staining of growth hormone and prolactin. Insulin-like growth factor-1 normalized as well.

CONCLUSIONS

Suppressed growth hormone after oral glucose tolerance test cannot exclude acromegaly, and some patients may have only mild or no clinical presentation of acromegaly. Patients with pituitary microadenoma or macroadenoma and elevated insulin-like growth factor-1 should be closely monitored for signs/symptoms of acromegaly and hypopituitarism.

摘要

背景

口服葡萄糖耐量试验后生长激素值≥1μg/L 可诊断肢端肥大症。然而,口服葡萄糖耐量试验后正常的生长激素抑制并不能排除肢端肥大症。

病例介绍

我们报告了一例 55 岁的中国男性,因交通事故意外发现垂体大腺瘤。他自述近几年脚变大。起初,生长激素值<1μg/L 时发现胰岛素样生长因子-1 升高,怀疑与骨折相关的胰岛素样生长因子-1升高。胰岛素样生长因子-1逐渐下降,但仍高于正常值上限。然而,1 年后他出现头晕,胰岛素样生长因子-1再次升高。此外,还出现了继发性皮质醇功能减退。垂体大腺瘤大小保持稳定。后续的口服葡萄糖耐量试验显示生长激素值>1μg/L。随后采用经鼻内镜入路切除垂体大腺瘤。垂体大腺瘤切除后,病理检查显示生长激素和催乳素阳性染色。胰岛素样生长因子-1也恢复正常。

结论

口服葡萄糖耐量试验后的抑制性生长激素不能排除肢端肥大症,有些患者可能仅有轻度或无肢端肥大症的临床表现。对于胰岛素样生长因子-1升高的垂体微腺瘤或大腺瘤患者,应密切监测肢端肥大症和垂体功能减退的迹象/症状。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1347/10404368/e8f878350b19/13256_2023_4064_Fig1_HTML.jpg

相似文献

引用本文的文献

本文引用的文献

1
Subclinical acromegaly: to treat or not to treat?亚临床肢端肥大症:治疗还是不治疗?
Endocr J. 2022 Nov 28;69(11):1323-1328. doi: 10.1507/endocrj.EJ22-0066. Epub 2022 Jun 22.
2
Diagnosis and Treatment of Acromegaly: An Update.肢端肥大症的诊断与治疗:最新进展。
Mayo Clin Proc. 2022 Feb;97(2):333-346. doi: 10.1016/j.mayocp.2021.11.007.
4
The Biochemical Diagnosis of Acromegaly.肢端肥大症的生化诊断
J Clin Med. 2021 Mar 9;10(5):1147. doi: 10.3390/jcm10051147.
5
Multidisciplinary management of acromegaly: A consensus.肢端肥大症的多学科管理:共识。
Rev Endocr Metab Disord. 2020 Dec;21(4):667-678. doi: 10.1007/s11154-020-09588-z. Epub 2020 Sep 10.
8
Acromegaly: an endocrine society clinical practice guideline.肢端肥大症:内分泌学会临床实践指南。
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51. doi: 10.1210/jc.2014-2700. Epub 2014 Oct 30.
10
Clinically silent somatotroph adenomas are common.临床上无功能的生长激素腺瘤很常见。
Eur J Endocrinol. 2011 Jul;165(1):39-44. doi: 10.1530/EJE-11-0216. Epub 2011 Apr 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验